Why Are NuCana Shares Moving Higher On Wednesday?

by Vandana Singh, Benzinga Editor

September 29, 2021 9:22 AM | 27 seconds read |

The FDA has granted Fast Track designation to NuCana plc's NCNA Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer.
The Company recently announced the enrollment of 418 evaluable patients in the Phase 3 study, which is expected to enable the first interim analysis in 1H of 2022.
Related content: Benzinga's Full FDA Calendar.
Price Action: NCNA stock is up 24.50% at $2.95 during the premarket session on the last check Wednesday.